## **Christine Johnston**

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3867038/christine-johnston-publications-by-year.pdf

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

3,250
citations

30
h-index

98
ext. papers

3,886
ext. citations

9.4
avg, IF

L-index

#	Paper	IF	Citations
85	Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity <i>JAMA Network Open</i> , <b>2022</b> , 5, e214	2 <del>796</del>	2
84	Diagnosis and Management of Genital Herpes: Key Questions and Review of the Evidence for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines <i>Clinical Infectious Diseases</i> , <b>2022</b> , 74, S134-S143	11.6	1
83	Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials <i>JAMA Network Open</i> , <b>2022</b> , 5, e2148325	10.4	2
82	HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV Antigens <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 867962	8.4	O
81	Characteristics of the Audience Reached by the National Network of Sexually Transmitted Disease Clinical Prevention Training Centers and Correlation With Sexually Transmitted Infection Rates, 2015 to 2020 Sexually Transmitted Diseases, 2022, 49, 313-317	2.4	
80	Comparison of herpes simplex virus 1 genomic diversity between adult sexual transmission partners with genital infection <i>PLoS Pathogens</i> , <b>2022</b> , 18, e1010437	7.6	2
79	Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report <b>2021</b> ,		32
78	Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. <i>EClinicalMedicine</i> , <b>2021</b> , 33, 100773	11.3	28
77	Uptake of treatment practice standards during a pandemic in an academic medical system. <i>Infection Control and Hospital Epidemiology</i> , <b>2021</b> , 1-2	2	
76	Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 224, 1372-1382	7	3
75	Impact of the menstrual cycle and ethinyl estradiol/etonogestrel contraceptive vaginal ring on granulysin and other mucosal immune mediators. <i>American Journal of Reproductive Immunology</i> , <b>2021</b> , 86, e13412	3.8	2
74	Leveraging E-Learning Infrastructure in Times of Rapid Change: Use of the National Sexually Transmitted Diseases Curriculum in the Era of COVID-19. <i>Sexually Transmitted Diseases</i> , <b>2021</b> , 48, S50-S.	5 <del>3</del> .4	1
73	The viral hypothesis: how herpesviruses may contribute to Alzheimer's disease. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	4
72	B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	6
71	Distinct populations of antigen-specific tissue-resident CD8+ T cells in human cervix mucosa. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	3
70	Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads. <i>PLoS Computational Biology</i> , <b>2021</b> , 17, e1009072	5	1
69	Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. <i>Journal of Medical Virology</i> , <b>2021</b> , 93, 2270-2280	19.7	20

68	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 344-352	8	36
67	Tissue-Resident-Memory CD8 T Cells Bridge Innate Immune Responses in Neighboring Epithelial Cells to Control Human Genital Herpes. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 735643	8.4	1
66	Large, Stable, Contemporary Interspecies Recombination Events in Circulating Human Herpes Simplex Viruses. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 221, 1271-1279	7	18
65	The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study. <i>BMJ Global Health</i> , <b>2020</b> , 5, e001875	6.6	22
64	Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. <i>Lancet Infectious Diseases, The</i> , <b>2020</b> , 20, e181-e191	25.5	13
63	An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa232	1	12
62	Subclinical Genital Herpes Shedding in HIV/Herpes Simplex Virus 2-Coinfected Women during Antiretroviral Therapy Is Associated with an Increase in HIV Tissue Reservoirs and Potentially Promotes HIV Evolution. <i>Journal of Virology</i> , <b>2020</b> , 95,	6.6	1
61	Covid-19, Ebola, and HIV - Leveraging Lessons to Maximize Impact. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, e106	59.2	9
60	Evaluation of the National Sexually Transmitted Disease Curriculum: Reach, Utilization, and Engagement. <i>Sexually Transmitted Diseases</i> , <b>2020</b> , 47, 412-418	2.4	2
59	Cytomegalovirus shedding from breastmilk and mucosal sites in healthy postpartum women: A pilot study. <i>Journal of Medical Virology</i> , <b>2019</b> , 91, 894-898	19.7	6
58	The Effect of Hormonal Contraception and Menstrual Cycle Timing on Genital Herpes Simplex Virus-2 Shedding and Lesions. <i>Sexually Transmitted Diseases</i> , <b>2019</b> , 46, 58-62	2.4	1
57	The National Network of Sexually Transmitted Disease Clinical Prevention Training Centers Turns 40-A Look Back, a Look Ahead. <i>Sexually Transmitted Diseases</i> , <b>2019</b> , 46, 487-492	2.4	3
56	Time Trends in First-Episode Genital Herpes Simplex Virus Infections in an Urban Sexually Transmitted Disease Clinic. <i>Sexually Transmitted Diseases</i> , <b>2019</b> , 46, 795-800	2.4	7
55	Ultrasensitive Capture of Human Herpes Simplex Virus Genomes Directly from Clinical Samples Reveals Extraordinarily Limited Evolution in Cell Culture. <i>MSphere</i> , <b>2018</b> , 3,	5	28
54	Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 1691-1699	7	12
53	Genome-Wide Surveillance of Genital Herpes Simplex Virus Type 1 From Multiple Anatomic Sites Over Time. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 595-605	7	20
52	Facilitation of Intensive Insulin Therapy in the Early Primary School Setting: Narratives of Australian Diabetes Educators. <i>Comprehensive Child and Adolescent Nursing</i> , <b>2018</b> , 41, 213-227	0.8	О
51	Worldwide circulation of HSV-2 [HSV-1 recombinant strains. <i>Scientific Reports</i> , <b>2017</b> , 7, 44084	4.9	49

50	Future prospects for new vaccines against sexually transmitted infections. <i>Current Opinion in Infectious Diseases</i> , <b>2017</b> , 30, 77-86	5.4	40
49	Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract. <i>Mucosal Immunology</i> , <b>2017</b> , 10, 1259-1269	9.2	38
48	Performance of Commercial Enzyme-Linked Immunoassays for Diagnosis of Herpes Simplex Virus-1 and Herpes Simplex Virus-2 Infection in a Clinical Setting. <i>Sexually Transmitted Diseases</i> , <b>2017</b> , 44, 763-7	674	9
47	Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 U and U regions from genital swabs collected from 3 continents. <i>Virology</i> , <b>2017</b> , 510, 90-98	3.6	11
46	Genital Herpes <b>2017</b> , 567-574.e2		
45	T Cell Immunity to Varicella-Zoster Virus in the Setting of Advanced HIV and Multiple Varicella-Zoster Virus Recurrences. <i>Viral Immunology</i> , <b>2017</b> , 30, 77-80	1.7	5
44	Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002475	11.6	14
43	A curative regimen would decrease HIV prevalence but not HIV incidence unless targeted to an ART-nalle population. <i>Scientific Reports</i> , <b>2016</b> , 6, 22183	4.9	3
42	Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons. <i>Infectious Agents and Cancer</i> , <b>2016</b> , 11, 7	3.5	8
41	Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses. <i>Journal of Immunology</i> , <b>2016</b> , 196, 2205-2218	5.3	36
40	Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 149-56	4.7	24
39	Status of vaccine research and development of vaccines for herpes simplex virus. <i>Vaccine</i> , <b>2016</b> , 34, 294	l8‡2952	<sup>2</sup> 94
38	Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. <i>Clinical Microbiology Reviews</i> , <b>2016</b> , 29, 149-61	34	100
37	Proliferative laryngitis with airway obstruction in an adult: Consider herpes. <i>Laryngoscope</i> , <b>2016</b> , 126, 945-8	3.6	8
36	In Situ Detection of Regulatory T Cells in Human Genital Herpes Simplex Virus Type 2 (HSV-2) Reactivation and Their Influence on Spontaneous HSV-2 Reactivation. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 23-31	7	12
35	Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 2495-2503	27.4	44
34	Herpes Simplex Virus Type 1 Shedding in Tears and Nasal and Oral Mucosa of Healthy Adults. Sexually Transmitted Diseases, <b>2016</b> , 43, 756-760	2.4	47
33	The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps. <i>Vaccine</i> , <b>2016</b> , 34, 2939-2947	4.1	76

## (2011-2015)

32	and Recommendation for Management. <i>Journal of the International Association of Providers of AIDS Care</i> , <b>2015</b> , 14, 300-5	1.7	14
31	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-nalle subjects. <i>Vaccine</i> , <b>2015</b> , 33, 5225-34	4.1	24
30	Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus. Journal of Infectious Diseases, <b>2015</b> , 212, 1022-31	7	34
29	Management of Acute Myeloid Leukemia in the Intensive Care Setting. <i>Journal of Intensive Care Medicine</i> , <b>2015</b> , 30, 375-84	3.3	5
28	Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 212, 1949-56	<b>6</b> 7	12
27	Current status and prospects for development of an HSV vaccine. <i>Vaccine</i> , <b>2014</b> , 32, 1553-60	4.1	51
26	Helicase-primase inhibitor pritelivir for HSV-2 infection. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 201-10	59.2	95
25	Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection. <i>Journal of Virology</i> , <b>2014</b> , 88, 4921-31	6.6	46
24	Human Herpesviruses: Herpes Simplex Virus Types 1 and 2 <b>2014</b> , 829-853		О
23	Immune surveillance by CD8⊞ skin-resident T cells in human herpes virus infection. <i>Nature</i> , <b>2013</b> , 494-7	50.4	209
23		50.4 3.1	209
	497, 494-7  High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. <i>Journal of Acquired Immune</i>		
22	High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 201-8  Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in	3.1	15
22	High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 201-8  Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. <i>ELife</i> , <b>2013</b> , 2, e00288  Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2	3.1	15 50
22 21 20	High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 201-8  Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. <i>ELife</i> , <b>2013</b> , 2, e00288  Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. <i>Lancet, The</i> , <b>2012</b> , 379, 641-7  Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in	3.1 8.9 40	15 50 90
22 21 20 19	High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 201-8  Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. <i>ELife</i> , <b>2013</b> , 2, e00288  Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. <i>Lancet</i> , <i>The</i> , <b>2012</b> , 379, 641-7  Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, 731-8  Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in	3.1 8.9 40 4.7	15 50 90 133
22 21 20 19	High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 201-8  Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. <i>ELife</i> , <b>2013</b> , 2, e00288  Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. <i>Lancet, The</i> , <b>2012</b> , 379, 641-7  Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, 731-8  Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 205, 703-12  Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with	3.1 8.9 40 4.7	15 50 90 133 22

14	HSV-2: in pursuit of a vaccine. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 4600-9	15.9	106
13	Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 499-504	7	24
12	Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. <i>Journal of Clinical Immunology</i> , <b>2010</b> , 30, 703-22	5.7	44
11	Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. <i>Sexually Transmitted Infections</i> , <b>2009</b> , 85, 270-5	2.8	20
10	Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. <i>Nature Medicine</i> , <b>2009</b> , 15, 886-92	50.5	298
9	Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. <i>PLoS ONE</i> , <b>2009</b> , 4, e4222	3.7	42
8	Herpes simplex virus viremia during primary genital infection. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 31-4	7	60
7	Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. <i>Journal of Virology</i> , <b>2005</b> , 79, 13974-83	6.6	215
6	Age-dependent resistance to lethal alphavirus encephalitis in mice: analysis of gene expression in the central nervous system and identification of a novel interferon-inducible protective gene, mouse ISG12. <i>Journal of Virology</i> , <b>2002</b> , 76, 11688-703	6.6	103
5	Identification of genes involved in the host response to neurovirulent alphavirus infection. <i>Journal of Virology</i> , <b>2001</b> , 75, 10431-45	6.6	87
4	Transcriptional activation of Salmonella typhimurium invasion genes by a member of the phosphorylated response-regulator superfamily. <i>Molecular Microbiology</i> , <b>1996</b> , 22, 715-27	4.1	179
3	Salmonella typhimurium secreted invasion determinants are homologous to Shigella Ipa proteins. <i>Molecular Microbiology</i> , <b>1995</b> , 18, 479-90	4.1	133
2	Herpes Simplex Virus Mistyping due to HSV-1 x HSV-2 Interspecies Recombination in Viral Gene Encoding Glycoprotein B		1
1	Increased oral Epstein-Barr virus shedding with HIV-1 co-infection is due to a combination of B cell activation and impaired cellular immune control		2